Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2020-10-01
Colecção:Cells
Assuntos:
TRAIL-R2
bispecific antibody
selinexor
survivin
T cells
Acesso em linha:https://www.mdpi.com/2073-4409/9/10/2231
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados